GSK3β regulates BCL2L12 and BCL2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl

Cell Cycle

Volumn 11, Issue 3, 2012, Pages 532-542

  Chou, Chia Hua ^a,b   Chou, An Kuo ^c,d   Lin, Ching Chih ^a   Chen, Wei Jay ^a   Wei, Chih Chang ^a   Yang, Ming Chang ^a,b,e   Hsu, Ching Mei ^b   Lung, For Wey ^f   Loh, Joon Khim ^c,g   Howng, Shen Long ^c,g   Hong, Yi Ren ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

BCL2L12; BCL2L12A; GBM; GSK3 ; LiCl; Phosphorylation; Staurosporine induced apoptosis

Indexed keywords

BIOLOGICAL MARKER; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; PEPTIDE FRAGMENT; PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL2L12; PROTEIN BCL2L12A; STAUROSPORINE; TAU PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DATA ANALYSIS; DNA LIBRARY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEDICAL RECORD; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SCREENING; SIGNAL TRANSDUCTION; TESTIS;

EID: 84863138257     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.3.19051     Document Type: Article

References (49)

1. Buckner JC. Factors influencing survival in highgrade gliomas. Semin Oncol 2003; 30:10-4; PMID:14765378; http://dx.doi.org/10.1053/j.seminoncol. 2003.11.031.
2. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344:114-23; PMID:11150363; http://dx.doi. org/10.1056/NEJM200101113440207.
3. Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P Jr, Hemmings BA, et al. GSK3β regulates differentiation and growth arrest in glioblastoma. PLoS One 2009; 4:7443; PMID:19823589; http://dx.doi. org/10.1371/journal.pone. 0007443.
4. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107:519-27; PMID:6249596; http://dx.doi. org/10.1111/j.1432-033.1980.tb06059.x.
5. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990; 9:2431-8; PMID:2164470.
6. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116:1175- 86; PMID:12615961; http://dx.doi.org/10.1242/ jcs.00384.
7. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29:95-102; PMID:15102436; http://dx.doi. org/10.1016/j.tibs.2003.12.004.
8. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2:769-76; PMID:11584304; http://dx.doi.org/10.1038/35096075.
9. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase- 3β participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65:2076-81; PMID:15781615; http://dx.doi.org/10.1158/0008-5472.CAN-04- 3642.
10. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q. Pharmacologic modulation of glycogen synthase kinase-3β promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 2005; 65:9012-20; PMID:16204075; http://dx.doi.org/10.1158/0008-5472. CAN-05-1226.
11. Beurel E, Jope RS. The paradoxical pro- and antiapoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006; 79:173-89; PMID:16935409; http://dx.doi. org/10.1016/j.pneurobio.2006.07. 006.
12. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008; 27:6398-406; PMID:18955968; http://dx.doi.org/10.1038/onc.2008.307.
13. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647-56; PMID:12209154; http://dx.doi. org/10.1038/nrc883.
14. Reed JC. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles and therapeutic opportunities. Cell Death Differ 2006; 13:1378- 86; PMID:16729025; http://dx.doi.org/10.1038/ sj.cdd.4401975.
15. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005; 5:189-200; PMID:15719025; http://dx.doi.org/10.1038/nri1568.
16. Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK, Kwamie A, Diamandis EP. Molecular cloning, physical mapping and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. Genomics 2001; 72:217-21; PMID:11401436; http:// dx.doi.org/10.1006/geno.2000.6455.
17. 2/M arrest in CHO cells. Mol Cell Biochem 2010; 333:323-30; PMID:19763795; http://dx.doi.org/10.1007/s11010- 009-0233-z.
18. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 2007; 21:98-111; PMID:17210792; http://dx.doi. org/10.1101/gad.1480007.
19. Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, et al. Bcl2L12-mediated inhibition of effector caspase 3 and caspase 7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 2008; 105:10703-8; PMID:18669646; http://dx.doi. org/10.1073/pnas.0712034105.
20. Stegh AH, Chin L, Louis DN, DePinho RA. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 2008; 7:2833-9; PMID:18769159; http://dx.doi. org/10.4161/cc.7.18.6759.
21. Stegh AH, Brennan C, Mahoney JA, Forloney KL, Jenq HT, Luciano JP, et al. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 2010; 24:2194-204; PMID:20837658; http://dx.doi. org/10.1101/gad.1924710.
22. Stegh AH, DePinho RA. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle 2011; 10:33-8; PMID:21200141; http://dx.doi.org/10.4161/cc.10.1.14365.
23. Cohen GB, Ren R, Baltimore D. Modular binding domains in signal transduction proteins. Cell 1995; 80:237-48; PMID:7834743; http://dx.doi. org/10.1016/0092-8674(95)90406-9.
24. Hong Y, Yang J, Wu W, Wang W, Kong X, Wang Y, et al. Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. Biochim Biophys Acta 2008; 1782:649-57; PMID:18930135.
25. Thomadaki H, Talieri M, Scorilas A. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett 2007; 247:48-55; PMID:16647810; http://dx.doi.org/10.1016/j.canlet. 2006.03.016.
26. Florou D, Papadopoulos IN, Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochem Biophys Res Commun 2010; 391:214-8; PMID:19903463; http:// dx.doi.org/10.1016/j.bbrc. 2009.11.034.
27. Mathioudaki K, Scorilas A, Papadokostopoulou A, Xynopoulos D, Arnogianaki N, Agnanti N, et al. Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biol Chem 2004; 385:779-83; PMID:15493871; http://dx.doi. org/10.1515/BC.2004.101.
28. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Scorilas A. BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. Mol Med 2011; 17:163-71; PMID:21152697; http://dx.doi.org/10.2119/ molmed.2010.00056.
29. Papageorgiou SG, Kontos CK, Pappa V, Thomadaki H, Kontsioti F, Dervenoulas J, et al. The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker. Oncologist 2011; 16:1280-91; PMID:21737576; http://dx.doi. org/10.1634/theoncologist.2010-0349.
30. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, et al. C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 2000; 113:3737-45; PMID:11034902.
31. Mookherjee P, Johnson GV. Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells. Brain Res 2001; 921:31-43; PMID:11720709; http:// dx.doi.org/10.1016/S0006-8993(01)03074-8.
32. Toumelin GL, Mazars A, Licznar A, Guasconi G, Rain JC, Cauquil N, et al. BCL2L12, a new BH2 BH3 containing protein, substrate for GSK3β, mediates UV induced apoptosis. Proc Am Assoc Cancer Res 2006; 47:4073.
33. Nakajima A, Nishimura K, Nakaima Y, Oh T, Noguchi S, Taniguchi T, et al. Cell type-dependent proapoptotic role of Bcl2L12 revealed by a mutation concomitant with the disruption of the juxtaposed Irf3 gene. Proc Natl Acad Sci USA 2009; 106:12448- 52; PMID:19617565; http://dx.doi.org/10.1073/ pnas.0905702106.
34. Morel C, Carlson SM, White FM, Davis RJ. Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol Cell Biol 2009; 29:3845-52; PMID:19433446; http://dx.doi. org/10.1128/MCB.00279-09.
35. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and destruction. Oncotarget 2011; 2:239-44; PMID:21608150.
36. Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA, et al. Glycogen synthase kinase-3β phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 2004; 24:9993-10002; PMID:15525785; http:// dx.doi.org/10.1523/JNEUROSCI.2057-04.2004.
37. Duncan CG, Yan H. Genomic alterations and the pathogenesis of glioblastoma. Cell Cycle 2011; 10:1174-5; PMID:21389786; http://dx.doi. org/10.4161/cc.10.8.15225.
38. Wolf A, Agnihotri S, Guha A. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 2010; 1:552-62; PMID:21317451.
39. Hercbergs AH, Lin HY, Davis FB, Davis PJ, Leith JT. Radiosensitization and production of DNA doublestrand breaks in U87MG brain tumor cells induced by tetraiodothyroacetic acid (tetrac). Cell Cycle 2011; 10:352-7; PMID:21212737; http://dx.doi. org/10.4161/cc.10.2.14641.
40. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration and invasion in glioblastoma multiforme cells. Oncotarget 2011.
41. Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2011; 2:646-53; PMID:21896960.
42. Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, et al. miR-101 is downregulated in glioblastoma resulting in EZH2-induced proliferation, migration and angiogenesis. Oncotarget 2010; 1:710-20; PMID:21321380.
43. Li X, Jope RS. Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 2010; 35:2143-54; PMID:20668436; http://dx.doi. org/10.1038/npp.2010.105.
44. Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 2011; 4:16; PMID:21886606; http://dx.doi. org/10.3389/fnmol.2011.00016.
45. Marmol F. Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1761-71; PMID:18789369; http://dx.doi.org/10.1016/j.pnpbp.2008.08.012.
46. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007; 26:186- 97; PMID:16819506; http://dx.doi.org/10.1038/ sj.onc.1209785.
47. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330.
48. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109; PMID:17618441; http://dx.doi.org/10.1007/s00401- 007-0243-4.
49. Zhu L. Yeast GAL4 two-hybrid system. A genetic system to identify proteins that interact with a target protein. Methods Mol Biol 1997; 63:173-96; PMID:9113650.